U057 Medical Dermatology Potpourri: Challenges Faced and Lessons Learned
DESCRIPTION
The medical literature is constantly evolving, forcing us to reconsider our practice approach. This session will highlight clinical pearls in the evaluation, treatment, and monitoring of complex medical dermatology disorders. Treatment strategies based on the latest available data in the literature will be discussed. This session is geared toward general dermatologists and residents in training.
LEARNING OBJECTIVES
Summarize latest updates and findings in the literature for medical dermatology.
Apply new concepts from the literature to the daily practice of medical dermatology.
DIRECTOR
Arash Mostaghimi, MD, MPH, FAAD
SPEAKER
Caroline Nelson, MD, FAAD
DISCLOSURES
Arash Mostaghimi, MD, MPH, FAAD
AbbVie – Consultant(Fees); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Advisory Board(Fees), Investigator(Grants/Research Funding); Equillium, Inc. – Consultant(Fees); Hims – Advisory Board(Honoraria); Incyte Corporation – Investigator(Grants/Research Funding); Indomo – Consultant (1099 relationship)(Fees); Legacy Healthcare – Consultant (1099 relationship)(Fees); Olaplex – Advisory Board(Fees); Pelage Pharmaceuticals – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Fees), Consultant(Fees); Q32 Bio Inc. – Consultant (1099 relationship)(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees);
Caroline Nelson, MD, FAAD
Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding);